Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
39.16
Nov 06 • 3:59 PM ET Dollar change+1.78 Percentage change(4.76%)
Aftermarket Close
39.00
Aftermarket • 7:30 PM ET Dollar change-0.16 Percentage change(-0.41%)
Index
RUT
Market Cap
1.72B
Enterprise Value
1.44B
Income
-122.90M
Sales
613.81M
Book/sh
34.51
Cash/sh
7.49
Employees
3000
IPO
Feb 02, 1995
P/E
-
Forward P/E
82.01
PEG
7.55
P/S
2.79
P/B
1.13
P/C
5.23
P/FCF
173.64
EV/EBITDA
36.11
EV/Sales
2.35
Quick Ratio
2.21
Current Ratio
2.50
Debt/Eq
0.04
LT Debt/Eq
0.04
Option/Short
Yes / Yes
EPS (ttm)
-2.67
EPS next Y
0.48
EPS next Q
0.11
EPS this Y
-37.64%
EPS next Y
50.14%
EPS next 5Y
10.86%
EPS past 3/5Y
40.29% -
Sales past 3/5Y
2.25% 8.85%
EPS Y/Y TTM
-9.38%
Sales Y/Y TTM
1.47%
EPS Q/Q
104.70%
Sales Q/Q
11.97%
Insider Own
1.57%
Insider Trans
1.53%
Inst Own
114.52%
Inst Trans
-4.58%
ROA
-5.75%
ROE
-7.04%
ROIC
-7.86%
Gross Margin
44.05%
Oper. Margin
-2.57%
Profit Margin
-20.02%
SMA20
4.59%
SMA50
10.87%
SMA200
38.35%
Trades
Shs Outstand
43.76M
Shs Float
43.12M
52W High
46.41 -15.62%
52W Low
15.93 145.83%
Volatility
6.92% 5.87%
ATR (14)
2.27
RSI (14)
55.43
Beta
1.46
Rel Volume
0.83
Avg Volume
959.47K
Volume
792,118
Perf Week
0.26%
Perf Month
8.78%
Perf Quarter
17.49%
Perf Half Y
103.75%
Perf YTD
17.74%
Perf Year
32.52%
Perf 3Y
-19.61%
Perf 5Y
-68.14%
Perf 10Y
203.80%
Prev Close
37.38
Price
39.16
Change %
4.76%
Consensus
Buy
Avg. Price Target
$37.80
Implied Upside
-3.5%
Analysts7incl. previous ratings
Rating Distribution5 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jan 05, 2026Upgrade
EVR logoEEvercore ISI
In-line → Outperform$50+27.7%
Dec 19, 2025Reiterated
NNeedham
Buy$42 → $44+12.4%
Oct 30, 2025Upgrade
JEF logoJJefferies
Hold → Buy$38-3.0%
Aug 06, 2025Upgrade
RJF logoRRaymond James
Mkt Perform → Outperform$35-10.6%
Jul 22, 2025Resumed
SStephens
Equal-Weight$35-10.6%
Dec 18, 2024Upgrade
SStephens
Equal-Weight → Overweight$50 → $60+53.2%
Apr 04, 2024Initiated
JEF logoJJefferies
Hold$64+63.4%
Feb 01, 2024Reiterated
RILY logoRB. Riley Securities
Buy$61 → $79+101.7%
Jul 19, 2023Initiated
RJF logoRRaymond James
Mkt Perform
May 10, 2023Downgrade
KEY logoKKeyBanc Capital Markets
Overweight → Sector Weight
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Starr EphraimSVP, Gen Counsel & SecretaryJul 31 '26Buy24.173358,09668,728Aug 04 06:11 PM
Cornog William LDirectorMay 18 '26Buy16.3810,000163,80019,703May 19 04:10 PM
Azenta, Inc. is a global provider of life sciences solutions, enabling organizations worldwide to bring impactful breakthroughs and therapies to market faster. The company offers a suite of reliable cold-chain sample management solutions and multiomics services supporting drug development, clinical research, and advanced cell therapies for pharmaceutical, biotechnology, academic, and healthcare institutions globally. It operates through the following segments: Sample Management Solutions and Multiomics. The Sample Management Solutions segment provides end-to-end sample management products and services, including Sample Repository Services (SRS). Its core products include automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled-rate thawing devices. The Multiomics segment delivers genomic and other sample analysis services, including gene sequencing, gene synthesis, and related services. The company was founded in 1978 and is headquartered in Burlington, MA.
Ph.D.Dr. Martin D. Madaus D.V.M.
Executive VP & CFOMr. Lawrence Y. Lin
Senior VPMr. Ephraim Starr
Senior VP & Chief HR OfficerMs. Olga Pirogova
AdvisorDr. Ginger Zhou Ph.D.